Trials6 min read
Semaglutide Cuts Heart Risk 29% More Than Tirzepatide
New STEER study: semaglutide cut major cardiac events 29% more than tirzepatide in obesity patients without diabetes. What it means for stack choice.
Peptide Trials News
Phase readouts, head-to-head studies, pipeline data.
Daily Peptide News
New articles delivered to your inbox every morning. Free.
Trials News
Trials7 min read
Semaglutide Reverses Knee Cartilage: New Study
May 2026 research: semaglutide reverses knee cartilage damage independent of weight loss. MRI showed 17% thicker cartilage. What it means.
Trials6 min read
Retatrutide Tingling: 20.9% Hit by Dysesthesia
TRIUMPH-4 Phase 3 found 1 in 5 patients on retatrutide 12mg develop dysesthesia. What it feels like, why it happens, and how to manage it without quitting.
Trials8 min read
GLP-1 for Alzheimer's: 2026 Trial Results (Mixed)
Semaglutide EVOKE trial missed its primary endpoint. Liraglutide ELAD showed 50% less brain volume loss. What the 2026 data means for GLP-1 peptide buyers.
Trials11 min read
Retatrutide Phase 3: 28.7% Weight Loss
TRIUMPH-4 showed 28.7% weight loss at 68 weeks — surpassing every competitor. Phase 3 results, safety data, and timeline.